Fda approves first-of-its-kind sensight™ directional lead system for dbs therapy

Dublin, june 7, 2021 /prnewswire/ -- medtronic plc (nyse:mdt), the global leader in medical technology, today announced the u.s. food and drug administration (fda) approval and first u.s. implants of the sensight™ directional lead system used for deep brain stimulation (dbs) therapy. sensight is the first-of-its-kind dbs directional lead that combines the benefits of directionality with the power of sensing, allowing physicians to deliver precise, patient-specific dbs therapy for the treatment of some symptoms associated with movement disorders like parkinson's disease, dystonia and essential tremor, and medically refractory epilepsy.
MDT Ratings Summary
MDT Quant Ranking